四川双马股价下跌1.82% 子公司获欧盟原料药出口资质

Core Viewpoint - Sichuan Shuangma's stock price experienced a decline of 1.82% on July 30, closing at 19.44 yuan, with a trading volume of 136,800 hands and a transaction amount of 266 million yuan [1][2]. Group 1: Business Overview - Sichuan Shuangma operates in two main sectors: cement building materials and biopharmaceuticals [1]. - The company has two cement production lines with an annual capacity of 2 million tons and two aggregate production lines with an annual capacity of 5 million tons [1]. - In the biopharmaceutical sector, the company, through its subsidiary Hubei Jianxiang, is involved in the raw material pharmaceutical business [1]. Group 2: Recent Developments - Hubei Jianxiang Biopharmaceutical Co., Ltd., a subsidiary of Sichuan Shuangma, recently received the "Export EU Raw Material Drug Certification Document" from the Hubei Provincial Drug Administration, and its liraglutide production line passed the GMP compliance inspection [1]. - This certification is expected to help the company expand into international markets and enhance product competitiveness [1]. - The company has stated that it has not yet participated in the Yarlung Tsangpo River hydropower project [1]. Group 3: Market Activity - On July 30, the main funds for Sichuan Shuangma saw a net outflow of 18.2757 million yuan [2].